| Code | CSB-RA878853MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to atinumab, targeting RTN4 (Reticulon-4), also known as Nogo-A. RTN4 is a membrane protein predominantly expressed in the central nervous system and functions as a potent inhibitor of neurite outgrowth and axonal regeneration. This protein plays a critical role in limiting neural plasticity and repair following injury by interacting with the Nogo receptor complex on neurons. RTN4 has been implicated in various neurological conditions, including spinal cord injury, stroke, and multiple sclerosis, where its inhibitory effects on axonal regeneration contribute to impaired functional recovery. Additionally, RTN4 expression has been observed in certain cancers, suggesting potential roles in tumor biology.
Atinumab represents an investigational therapeutic antibody designed to neutralize RTN4's inhibitory effects, thereby promoting neural regeneration and functional recovery in neurological disorders. This biosimilar antibody provides researchers with a valuable tool for investigating RTN4-mediated signaling pathways, studying mechanisms of neural regeneration, and exploring therapeutic strategies for neurodegenerative diseases and neurotrauma. The antibody supports various research applications aimed at understanding the complex role of RTN4 in nervous system pathology and repair.
There are currently no reviews for this product.